Risk and benefit for targeted therapy agents in paediatric phase I trials in oncology: a systematic review and meta-analysis protocol.

Ostrowska J, Strzebonska K, Waligora M

Open source

DOI
10.1136/bmjopen-2026-123756
Published
2026 Sep 11
Container
BMJ open
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1136/bmjopen-2026-123756,
  title = {Risk and benefit for targeted therapy agents in paediatric phase I trials in oncology: a systematic review and meta-analysis protocol.},
  author = {Ostrowska J and Strzebonska K and Waligora M},
  year = {2026},
  journal = {BMJ open},
  doi = {10.1136/bmjopen-2026-123756},
  url = {https://doi.org/10.1136/bmjopen-2026-123756}
}

RIS

TY  - JOUR
TI  - Risk and benefit for targeted therapy agents in paediatric phase I trials in oncology: a systematic review and meta-analysis protocol.
AU  - Ostrowska J
AU  - Strzebonska K
AU  - Waligora M
PY  - 2026
JO  - BMJ open
DO  - 10.1136/bmjopen-2026-123756
UR  - https://doi.org/10.1136/bmjopen-2026-123756
ER  - 

APA

J, O., K, S., & M, W. (2026). Risk and benefit for targeted therapy agents in paediatric phase I trials in oncology: a systematic review and meta-analysis protocol.. BMJ open. https://doi.org/10.1136/bmjopen-2026-123756

Source records